A pluridimensional view of biased agonism

Molecular Pharmacology

Volumn 90, Issue 5, 2016, Pages 587-595

  Costa Neto, Claudio M ^a   Parreiras E Silva, Lucas T ^a,b   Bouvier, Michel ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; ASIMADOLINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND;

DATA ANALYSIS; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; INTRACELLULAR SPACE; LIGAND BINDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RECEPTOR BINDING ASSAY; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; KINETICS; METABOLISM;

ANIMALS; HUMANS; KINETICS; MODELS, BIOLOGICAL; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84992724100     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.105940     Document Type: Review

References (89)

1. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 97: 3684-3689.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Piñeyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
3. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of betablockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
4. Barker EL, Westphal RS, Schmidt D, and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
5. Benovic JL, Kühn H, Weyand I, Codina J, Caron MG, and Lefkowitz RJ (1987) Functional desensitization of the isolated beta-adrenergic receptor by the betaadrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci USA 84:8879-8882.
6. Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, Caron MG, and Lefkowitz RJ (1985) Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase: regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem 260:7094-7101.
7. Bond R, Milligan G, and Bouvier M (2001) Inverse agonism, in Handbook of Experimental Pharmacology: the Pharmacology of Functional, Biochemical, and Recombinant Receptor System (Kenakin T and Angus JA eds) vol 148, pp 167-182, Springer-Verlag, Heidelberg.
8. Bouvier M, Hausdorff WP, De Blasi A, O'Dowd BF, Kobilka BK, Caron MG, and Lefkowitz RJ (1988) Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature 333:370-373.
9. Bouvier M, Leeb-Lundberg LM, Benovic JL, Caron MG, and Lefkowitz RJ (1987) Regulation of adrenergic receptor function by phosphorylation. II. Effects of agonist occupancy on phosphorylation of alpha 1- and beta 2-adrenergic receptors by protein kinase C and the cyclic AMP-dependent protein kinase. J Biol Chem 262: 3106-3113.
10. Broad J, Maurel D, Kung VW, Hicks GA, Schemann M, Barnes MR, Kenakin TP, Granier S, and Sanger GJ (2016) Human native kappa opioid receptor functions not predicted by recombinant receptors: implications for drug design. Sci Rep 6: 30797.
11. Brown JH and Goldstein D (1986) Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cells. Mol Pharmacol 30:566-570.
12. Burch RM, Luini A, and Axelrod J (1986) Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells. Proc Natl Acad Sci USA 83:7201-7205.
13. Busnelli M, Saulière A, Manning M, BouvierM, Galés C, and Chini B (2012) Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 287:3617-3629.
14. Calebiro D, Nikolaev VO, and Lohse MJ (2010) Imaging of persistent cAMP signaling by internalized G protein-coupled receptors. J Mol Endocrinol 45:1-8.
15. Charest PG, Terrillon S, and Bouvier M (2005) Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep 6:334-340.
16. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45:490-499.
17. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
18. Costa T, Lang J, Gless C, and Herz A (1990) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol Pharmacol 37:383-394.
19. Décaillot FM, Rozenfeld R, Gupta A, and Devi LA (2008) Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci USA 105: 16045-16050.
20. Deupi X and Kobilka BK (2010) Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology 25:293-303.
21. Devost D, Audet N, Zhou C, Kobayashi H, Bonin H, Lukashova V, Le Gouill C, Bouvier M, and Hébert TE (2016) Cellular and subcellular context determine outputs from signaling biosensors. Methods Cell Biol 132:319-337.
22. Dohlman HG, Thorner J, Caron MG, and Lefkowitz RJ (1991) Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60:653-688.
23. Eason MG, Jacinto MT, and Liggett SB (1994) Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Mol Pharmacol 45:696-702.
24. Eichel K, Jullié D, and von Zastrow M (2016) b-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat Cell Biol 18: 303-310.
25. Federman AD, Conklin BR, Schrader KA, Reed RR, and Bourne HR (1992) Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356:159-161.
26. Feinstein TN, Wehbi VL, Ardura JA, Wheeler DS, Ferrandon S, Gardella TJ, and Vilardaga JP (2011) Retromer terminates the generation of cAMP by internalized PTH receptors. Nat Chem Biol 7:278-284.
27. Feinstein TN, Yui N, Webber MJ, Wehbi VL, Stevenson HP, King JD, Jr, Hallows KR, Brown D, Bouley R, and Vilardaga JP (2013) Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem 288: 27849-27860.
28. Ferguson SS, Downey WE, 3rd, Colapietro AM, Barak LS, Ménard L, and Caron MG (1996) Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-366.
29. Galés C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, Paris H, and Bouvier M (2006) Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13:778-786.
30. Garcia-Sáinz JA (1987) Pathways of alpha 1-adrenergic action: comparison with V1- vasopressin and A1-angiotensin. Circ Res 61:II1-II5.
31. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, et al. (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100:11086-11091.
32. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of mu- and delta-opioid receptors: generation of novel functional properties. J Biol Chem 275:26128-26135.
33. Guo D, Dijksteel GS, van Duijl T, Heezen M, Heitman LH, and IJzerman AP (2016) Equilibrium and kinetic selectivity profiling on the human adenosine receptors. Biochem Pharmacol 105:34-41.
34. Guo D, Hillger JM, IJzerman AP, and Heitman LH (2014) Drug-target residence time: a case for G protein-coupled receptors. Med Res Rev 34:856-892.
35. Head BP, Patel HH, and Insel PA (2014) Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta 1838:532-545.
36. Henzler-Wildman K and Kern D (2007) Dynamic personalities of proteins. Nature 450:964-972.
37. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, Rasmussen SG, Sunahara RK, El-Samad H, Huang B, et al. (2013) Conformational biosensors reveal GPCR signalling from endosomes. Nature 495:534-538.
38. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, and Johnson GL (1998) [D-Arg1, D-Phe5, D-Trp7, 9, Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273:3097-3104.
39. Jiang LI, Collins J, Davis R, Lin KM, DeCamp D, Roach T, Hsueh R, Rebres RA, Ross EM, Taussig R, et al. (2007) Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J Biol Chem 282:10576-10584.
40. Kelly E, Rooney TA, and Nahorski SR (1985) Pertussis toxin separates two muscarinic receptor-effector mechanisms in the striatum. Eur J Pharmacol 119:129-130.
41. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
42. Kenakin T (2014) What is pharmacological 'affinity'? Relevance to biased agonism and antagonism. Trends Pharmacol Sci 35:434-441.
43. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216.
44. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3: 193-203.
45. Kenakin TP and Morgan PH (1989) Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol 35:214-222.
46. Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, Charlton SJ, et al. (2016) The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun 7:10842.
47. Leduc M, Breton B, Galés C, Le Gouill C, Bouvier M, Chemtob S, and Heveker N (2009) Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther 331:297-307.
48. Lee MH, Appleton KM, Strungs EG, Kwon JY, Morinelli TA, Peterson YK, Laporte SA, and Luttrell LM (2016) The conformational signature of b-arrestin2 predicts its trafficking and signalling functions. Nature 531:665-668.
49. Leeb-Lundberg LM, Mathis SA, and Herzig MC (1994) Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem 269:25970-25973.
50. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677-18680.
51. Lefkowitz RJ, Hausdorff WP, and Caron MG (1990) Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci 11:190-194.
52. Levitt ES, Clark MJ, Jenkins PM, Martens JR, and Traynor JR (2009) Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase. J Biol Chem 284:22108-22122.
53. Lohse MJ, Benovic JL, Codina J, Caron MG, and Lefkowitz RJ (1990) beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547-1550.
54. Lohse MJ, Nuber S, and Hoffmann C (2012) Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev 64:299-336.
55. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, et al. (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
56. Luttrell LM and Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465
57. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, and Lefkowitz RJ (2001) Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449-2454.
58. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, and Lefkowitz RJ (2000) Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574-1577.
59. Milano SK, Pace HC, Kim YM, Brenner C, and Benovic JL (2002) Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 41: 3321-3328.
60. Murayama T and Ui M (1985) Receptor-mediated inhibition of adenylate cyclase and stimulation of arachidonic acid release in 3T3 fibroblasts: selective susceptibility to islet-activating protein, pertussis toxin. J Biol Chem 260:7226-7233.
61. Nambi P, Peters JR, Sibley DR, and Lefkowitz RJ (1985) Desensitization of the turkey erythrocyte beta-adrenergic receptor in a cell-free system: evidence that multiple protein kinases can phosphorylate and desensitize the receptor. J Biol Chem 260:2165-2171.
62. Namkung Y, Le Gouill C, Lukashova V, Kobayashi H, Hogue M, Khoury E, Song M, Bouvier M, and Laporte SA (2016) Monitoring G protein-coupled receptor and b-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun 7:12178.
63. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang TY, Bressler EA, Hara MR, et al. (2011) Distinct phosphorylation sites on the b(2)- adrenergic receptor establish a barcode that encodes differential functions of b-arrestin. Sci Signal 4:ra51.
64. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu CW, Fung JJ, Bokoch MP, et al. (2013) The dynamic process of b(2)-adrenergic receptor activation. Cell 152:532-542.
65. Oates J and Watts A (2011) Uncovering the intimate relationship between lipids, cholesterol and GPCR activation. Curr Opin Struct Biol 21:802-807.
66. Pontier SM, Percherancier Y, Galandrin S, Breit A, Galés C, and Bouvier M (2008) Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem 283:24659-24672.
67. Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt SW, 3rd, and Bouvier M (2013) Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA 110:E5088-E5097.
68. Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064.
69. Samama P, Pei G, Costa T, Cotecchia S, and Lefkowitz RJ (1994) Negative antagonists promote an inactive conformation of the b 2-adrenergic receptor. Mol Pharmacol 45:390-394.
70. Santos GA, Duarte DA, Parreiras-E-Silva LT, Teixeira FR, Silva-Rocha R, Oliveira EB, Bouvier M, and Costa-Neto CM (2015) Comparative analyses of downstream signal transduction targets modulated after activation of the AT1 receptor by two b-arrestin-biased agonists. Front Pharmacol 6:131.
71. Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, Hansen JL, et al. (2012) Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 8:622-630.
72. Schann S, Bouvier M, and Neuville P (2013) Technology combination to address GPCR allosteric modulator drug-discovery pitfalls. Drug Discov Today Technol 10:e261-e267.
73. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175.
74. Stallaert W, Christopoulos A, and Bouvier M (2011) Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 6:811-825.
75. Szakadáti G, Tóth AD, Oláh I, Erdélyi LS, Balla T, Várnai P, Hunyady L, and Balla A (2015) Investigation of the fate of type I angiotensin receptor after biased activation. Mol Pharmacol 87:972-981.
76. Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, and Canals M (2016) Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. Biochem Pharmacol 113:70-87.
77. Tsvetanova NG and von Zastrow M (2014) Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat Chem Biol 10:1061-1065.
78. van der Westhuizen ET, Breton B, Christopoulos A, and Bouvier M (2014) Quantification of ligand bias for clinically relevant b2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85:492-509.
79. Vilardaga JP, Gardella TJ, Wehbi VL, and Feinstein TN (2012) Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci 33:423-431.
80. Vilardaga JP, Jean-Alphonse FG, and Gardella TJ (2014) Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol 10:700-706.
81. Wehbi VL, Stevenson HP, Feinstein TN, Calero G, Romero G, and Vilardaga JP (2013) Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gbg complex. Proc Natl Acad Sci USA 110:1530-1535.
82. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
83. Wess J (1997) G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354.
84. Wiley HS and Burke PM (2001) Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2:12-18.
85. Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, and Caron MG (1997) Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5:193-199.
86. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, and Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162.
87. Zhang X, Stevens RC, and Xu F (2015) The importance of ligands for G proteincoupled receptor stability. Trends Biochem Sci 40:79-87.
88. Zidar DA, Violin JD, Whalen EJ, and Lefkowitz RJ (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 106:9649-9654.
89. Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, and Laporte SA (2012) Differential b-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal 5:ra33.